"Naszą misją jest ułatwianie dostępu do nowoczesnych terapii leczniczych. Nowe leki to szansa na poprawę jakości życia dla pacjenta i przyszłych pokoleń. KO-MED Centra Kliniczne to sieć nowoczesnych i prężnie działających ośrodków, które każdego dnia przyjmują dziesiątki pacjentów z całej Polski. Naszą misją jest realizacja projektów badawczych, które stanowią szansę na odzyskanie zdrowia i przyczyniają się do rozwoju medycyny. Działalność prowadzimy od 20 lat, mając na koncie setki przeprowadzonych badań klinicznych. KO-MED Centra Kliniczne to gwarancja wysokiej jakości, efektywności i bezpieczeństwa prowadzonych badań. Na pierwszym miejscu zawsze stawiamy dobro pacjenta."

During the past decade, KO-MED Centra Kliniczne Zamosc conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 9 clinical trials were completed, i.e. on average, 81.8% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 5 clinical trials were completed. i.e. 166.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "KO-MED Centra Kliniczne Zamosc" #1 sponsor was "Pfizer" with 3 trials, followed by "Genentech, Inc." with 2 trials sponsored, "R-Pharm International, LLC" with 2 trials sponsored, "Bayer" with 1 trials sponsored and "Boehringer Ingelheim" with 1 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "KO-MED Centra Kliniczne Zamosc" #1 collaborator was "OCT Clinical Trials" with 2 trials as a collaborator, "Quintiles, Inc." with 2 trials as a collaborator, "Brigham and Women's Hospital" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator and "IQVIA Pvt. Ltd" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "KO-MED Centra Kliniczne Zamosc" are "Rheumatoid Arthritis" (4 trials), "Atrial Fibrillation" (2 trials), "Cardiovascular Disease" (2 trials), "Chronic Plaque Psoriasis" (1 trials) and "Diabetes Mellitus, Type 2" (1 trials). Many other conditions were trialed in "KO-MED Centra Kliniczne Zamosc" in a lesser frequency.

Most popular intervention types in "KO-MED Centra Kliniczne Zamosc" are "Drug" (12 trials), "Biological" (2 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "GDC-0853" (2 trials), "bococizumab (PF-04950615)" (2 trials), "Adalimumab" (1 trials) and "Adalimumab 40mg q2w" (1 trials). Other intervention names were less common.

The vast majority of trials in "KO-MED Centra Kliniczne Zamosc" are 14 trials for "All" genders.

Currently, there are NaN active trials in "KO-MED Centra Kliniczne Zamosc". undefined are not yet recruiting, 3 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in KO-MED Centra Kliniczne Zamosc, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in KO-MED Centra Kliniczne Zamosc, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".